Study Evaluating Trastuzumab Deruxtecan Treatment for Adults with Unresectable or Metastatic HER2-low or HER2 IHC 0 Breast Cancer Including Hormone Receptor-negative and Positive Types
Led by Daiichi Sankyo · Updated on 2026-06-12
250
Participants Needed
88
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating trastuzumab deruxtecan T-DXd for adults with unresectable or metastatic breast cancer that is either HER2-low or HER2 IHC 0. This includes patients with hormone receptor-negative and hormone receptor-positive types. The study aims to assess the safety and effectiveness of T-DXd, focusing on how long patients benefit from this treatment before needing the next anticancer therapy.
Participants receive T-DXd intravenously at a dose of 5.4 mgkg on the first day of each 21-day cycle. Treatment continues until disease progression, unacceptable side effects, other criteria for stopping, or two years after the first dose. The study includes four groups based on hormone receptor status and HER2 classification, with participants having had one to two prior treatments for metastatic breast cancer.
During the study, participants will have regular assessments including imaging scans to measure tumors, blood tests to monitor organ function, and questionnaires to evaluate quality of life. Researchers will track the time to next treatment, progression-free survival, response rates, adverse events, and changes in patient-reported outcomes for up to 24 months. Safety monitoring and close follow-up will support participant well-being throughout the trial.
CONDITIONS
Brief Title
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Research Team
(
(US Sites) Daiichi Sankyo Contact for Clinical Trial Information
(
(Asia Sites) Daiichi Sankyo Contact for Clinical Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
T‑DxD (HR–/HR+; HER2‑low or HER2‑0)
Standard chemotherapy
What this option is
An investigational antibody‑drug conjugate (trastuzumab deruxtecan) given intravenously at 5.4 mg/kg every 21‑day cycle until progression, unacceptable toxicity, other discontinuation criteria, or up to two years.
Standard chemotherapy regimens (such as taxanes, capecitabine, or eribulin) are generally offered to patients with HER2‑low metastatic breast cancer after prior lines of therapy.
Role in the trial
Administered as the investigational treatment to all trial cohorts differentiated by hormone receptor and HER2 status.
Not included in the trial; represents real‑world comparator outside study context.
Primary use
To assess safety and efficacy of T‑DxD in various HR and HER2 expression-defined metastatic cohorts.
Standard systemic therapy option commonly used in this patient population after prior lines of therapy.
How administered or performed
Given by intravenous infusion every 21 days at 5.4 mg/kg.
Administered according to established schedules depending on chemotherapeutic agent (e.g. weekly or every 3 weeks intravenous dosing or oral regimens).
Evidence status
Efficacy and safety under investigation; prior DESTINY‑Breast 04 and related studies support potential benefit in HER2‑low disease.
Efficacy established historically through randomized trials in metastatic breast cancer not overexpressing HER2.
Important risks
Risks include known T‑DxD toxicities such as potential interstitial lung disease or other treatment‑related adverse events.
Chemotherapy carries risks such as neutropenia, fatigue, nausea, and other known side effects.
Important limitations
Non‑randomized cohort design lacks direct internal control and heterogeneity across HR and HER2 subgroups may limit clear comparison.
Lacks contemporary efficacy data in HER2‑low or HER2 0 metastatic breast cancer following multiple prior therapies in the context of ADC era.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Signed and dated informed consent
Willing to provide a new or archival biopsy from primary or metastatic tumor
Diagnosed with unresectable and/or metastatic breast cancer
Hormone receptor-negative or hormone receptor-positive status confirmed
HER2-low (IHC 1+ or 2+/ISH-) or HER2 IHC 0 status confirmed per guidelines
Never had HER2-positive status or prior anti-HER2 therapy in metastatic setting
Received one or two prior metastatic therapies
For hormone receptor-positive HER2-low: recurrent disease within 2 years of adjuvant endocrine therapy start or progression on CDK4/6 inhibitor within 12 months of completion or progression within first 12 months in metastatic setting
At least one measurable lesion by CT or MRI
Stable, small brain metastases allowed if asymptomatic and not needing urgent treatment
ECOG performance status 0 or 1
Life expectancy of at least 12 weeks
Left ventricular ejection fraction 50% or higher within 28 days before enrollment
Adequate organ and bone marrow function within 28 days before enrollment
Completed required treatment washout periods
Agree to use effective contraception if of reproductive potential
You will not qualify if you...
Prior treatment with an antibody drug conjugate
Uncontrolled or significant cardiovascular disease
Corrected QT interval prolongation
History or current interstitial lung disease or pneumonitis requiring steroids or suspected but not ruled out
Spinal cord compression or active central nervous system metastases
Multiple primary cancers within 3 years except certain treated cancers
Severe allergic reactions to drug substances or monoclonal antibodies
Uncontrolled infections requiring IV antibiotics, antivirals, or antifungals
Active primary immunodeficiency or uncontrolled HIV or hepatitis B or C
Received live attenuated vaccine within 30 days prior to first study drug dose
Unresolved toxicities from prior anticancer therapy above grade 1 except hair loss
Pregnant, breastfeeding, or planning pregnancy
Lung-specific significant illnesses
Autoimmune, connective tissue, or inflammatory disorders
Prior complete pneumonectomy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 2 years
Participants receive trastuzumab deruxtecan intravenously every 21 days until disease progression, unacceptable side effects, or up to two years after the first dose.
Every 21 days
Follow-up
Duration - Up to 24 months
Participants are monitored for safety, disease progression, and quality of life for up to 24 months after starting treatment.
Regular assessments including imaging and questionnaires
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Studying Key Non-coding RNAs and Their Interaction With Chromatin Remodeling in Breast Cancer Patients
Comparing 18F-FDG and 68Ga-FAPI-46 PET Scans in Women With ER-positive Breast Cancer
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Observational Study Comparing 3D and 2D Echocardiography for Early Heart Damage Detection in Patients Receiving Anthracyclines and HER2-Targeted Cancer Therapies
Study Comparing 3D-Printed Biodegradable Breast Implants, Traditional Breast-Conserving Surgery, and Silicone Implant Reconstruction for Breast Cancer Patients
Ultrahypofractionated 5-Session Whole Breast Radiotherapy with Boost versus Standard 15-Session Radiotherapy for Breast Cancer Patients with Unfavorable Characteristics
Phase II Study Comparing 5-Day vs. 9-Day Whole Breast Radiotherapy with Boost in Early-stage Breast Cancer
Evaluating 68Ga-FAPI PETCT for Checking Axillary Lymph Node Status After Neoadjuvant Therapy in Women with Breast Cancer
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Exploratory Study of 68Ga-SorB PETCT Imaging to Diagnose Sortilin-Positive Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The Suitability of Repurposed, Legacy HER2 Immunohistochemistry Assays for the Detection of HER2 Low and Ultralow Expression: Current Limitations and Potential Considerations.